Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ligand Binding and Linkage00:49

Ligand Binding and Linkage

4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

5.6K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K
Conserved Binding Sites01:49

Conserved Binding Sites

4.1K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.1K
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

6.5K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
6.5K
Ligand Binding Sites02:40

Ligand Binding Sites

12.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.6K
Gene Families01:57

Gene Families

8.7K
Gene families consist of groups of genes proposed to have originated from a common ancestor. Typically these arise through events in which a gene or genes are mistakenly duplicated during cell division. Unlike their parent genes (which are subject to selection pressure to maintain function), these gene copies do not need to preserve their sequences and may evolve at a relatively faster rate.
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
8.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-In-Human Safety, Pharmacokinetics, and Pharmacodynamics of VENT-02 Freebase, a CNS-Penetrant NLRP3 Inhibitor.

Clinical and translational science·2026
Same author

Discrepancies between Fundus Photography and Multimodal Imaging in Mapping of Choroidal Tumor Borders.

Ophthalmology science·2026
Same author

Dissection of innate-immune-ligand- and interferon-protein-mediated transcriptional responses in human THP1 cell states.

Communications biology·2026
Same author

Reducing hERG Inhibition in the Design of Potent and Bioavailable Indazole cGAS Inhibitors.

ACS medicinal chemistry letters·2026
Same author

Structural basis for Lamassu-based antiviral immunity and its evolution from DNA repair machinery.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

SARS-CoV-2 NSP14 inhibitor exhibits potent antiviral activity and reverses NSP14-driven host modulation.

Nature communications·2025

Related Experiment Video

Updated: May 21, 2025

Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli
07:26

Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli

Published on: December 26, 2020

3.9K

Structural insight into the cGAS active site explains differences between therapeutically relevant species.

Alexander M Skeldon1, Li Wang2, Nicolas Sgarioto1

  • 1Ventus Therapeutics, Saint-Laurent, QC, Canada.

Communications Chemistry
|March 23, 2025
PubMed
Summary
This summary is machine-generated.

Cyclic GMP-AMP synthase (cGAS) inhibitors were studied, revealing a key amino acid difference between human and mouse cGAS that affects potency. A novel inhibitor was engineered for broad species efficacy.

More Related Videos

Identifying the Binding Proteins of Small Ligands with the Differential Radial Capillary Action of Ligand Assay DRaCALA
09:26

Identifying the Binding Proteins of Small Ligands with the Differential Radial Capillary Action of Ligand Assay DRaCALA

Published on: March 19, 2021

3.4K
Capture Compound Mass Spectrometry - A Powerful Tool to Identify Novel c-di-GMP Effector Proteins
12:11

Capture Compound Mass Spectrometry - A Powerful Tool to Identify Novel c-di-GMP Effector Proteins

Published on: March 29, 2015

11.6K

Related Experiment Videos

Last Updated: May 21, 2025

Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli
07:26

Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli

Published on: December 26, 2020

3.9K
Identifying the Binding Proteins of Small Ligands with the Differential Radial Capillary Action of Ligand Assay DRaCALA
09:26

Identifying the Binding Proteins of Small Ligands with the Differential Radial Capillary Action of Ligand Assay DRaCALA

Published on: March 19, 2021

3.4K
Capture Compound Mass Spectrometry - A Powerful Tool to Identify Novel c-di-GMP Effector Proteins
12:11

Capture Compound Mass Spectrometry - A Powerful Tool to Identify Novel c-di-GMP Effector Proteins

Published on: March 29, 2015

11.6K

Area of Science:

  • Biochemistry and Molecular Biology
  • Drug Discovery and Medicinal Chemistry
  • Immunology and Inflammation

Background:

  • Cyclic GMP-AMP synthase (cGAS) is a critical intracellular DNA sensor initiating inflammatory pathways.
  • cGAS activation is implicated in various peripheral and neurological diseases, driving interest in its therapeutic targeting.
  • Understanding cGAS inhibitor mechanisms and species-specific activity is crucial for drug development.

Purpose of the Study:

  • To elucidate the binding mode of known cGAS inhibitors.
  • To identify the structural basis for differential potency across species (human vs. mouse).
  • To design novel cGAS inhibitors with improved interspecies efficacy.

Main Methods:

  • Structural analysis of cGAS inhibitor binding modes.
  • Biochemical, cellular, and in vivo assays to assess compound activity.
  • Structure-based drug design targeting conserved active site interactions.

Main Results:

  • A single amino acid substitution (Threonine to Isoleucine) in mouse cGAS explains reduced potency of certain inhibitors compared to human cGAS.
  • This substitution significantly impacts inhibitor binding and downstream cellular responses.
  • A novel chemical inhibitor was successfully designed with potent activity against both human and mouse cGAS.

Conclusions:

  • The study identifies a key structural determinant for interspecies cGAS inhibitor potency.
  • Structure-enabled design is effective for creating potent, broad-spectrum cGAS inhibitors.
  • This work provides a foundation for optimizing cGAS inhibitors and advancing preclinical translation.